Q4 2019 Earnings Call
Ladies and gentlemen, thank you for standing by I imagine your P.G. I call operator.
Welcome and thank you for joining high Jens Q4, 2019 earnings conference call webcast.
At this time all participants are in listen only mode. Please be advised that this call is being recorded at CPI Jens request and will be made available on their internet site.
The presentation will be followed by a question answer session.
I'd like to ask a question anyway Press star followed by one on your Touchtone telephone.
Please press the star Keith.
Operator assistance.
This time I like to introduce your host John Girardi, Vice President corporate Communications and Investor Relations.
Please go ahead.
Thank you I welcome to our conference call todays speakers today are carried Bernard the interim CEO Kaizen and also senior Vice President of our molecular diagnostics business and long Soccer's Chief Financial Officer also joined the C.C.B. Lowe from the IR team.
Please note that this call is being webcast live and will be archived on the investor section of our website at Www <unk> Dot com copy. The press release is also available in the same section.
Before we begin let me cover our safe Harbor statement the discussion in responses to your questions on this call reflect management's views as of today Wednesday February 2020, well be making statements or provide any response to your questions that state or intentions beliefs expectations or predictions of future. These constitute forward looking statements for the purpose.
The safe Harbor provisions.
These statements involve risks and uncertainties that could cause actual results to differ materially from those projected.
I didn't disclaims any intention or obligation to revise any forward looking statements for information. Please refer to our filings with the U.S. Securities Exchange Commission.
Additionally, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles. You can find a reconciliation of these figures the gap in the press release in the presentation for this call.
Now I'll turn it over the called Terry.
Thank you John.
Let me begin by your work I mean, all <unk> cough cold or would you. Please your true be aboard.
Talk to you are getting enough Stuart I would love score in October of two program My Jim.
As you have seen.
Yesterday after our performance for Q4 can imagine shows that cardioversion exceeded the updated outlook that we had said for the full walk it was girls and deliver on food Your says girls.
And at the same time, we exceeded the targets set for adjusted earnings.
As we go through dispute here the change occurred yesterday, we did even on that were commitments to you all to and we continue to focus on attractive growth opportunities.
Across the continuum from life science to more difficult diagnostic.
At the same time.
As we said also in our Q free.
<unk>.
We are realistic about our what challenges that began in mid two pulled on the 19. This fisher didn't usually a market spots because all the China.
I was worried that the decline in revenues from companion diagnostic could you broke mark do you trying to change you know will clearly cord injury your strategy announced in October.
I've spoken for going I'm, 20, we announced a bottoms outlook that sets out realistically ambitious goals that competes relies on growth opportunities in our sample to insight bought forward. Your wide also addressing the challenges that cover you will go up from two falls on a night you.
Hi, This is supposed to key message for today makes sense for the fourth quarter of nitrogen were $415.5 million on the world's focus on.
Constant exchange rates C. R. And this was ahead of our outlook for people starting to see all girls.
Adjusted earnings per share with 48 cents at constant exchange rate and also on a reported base.
This was once again above our outlook for 45 to 46 cents per share.
My second she May states for two days that we did he built under says outlook for the full year two fold them in my team I've also exceeded the target we that's it for registered abuse.
Net sales 19 were one important $53 billion.
Raising 4% I'd see our against our targets for girls <unk>.
The drop in companion diagnostic codes, you broke month when he was related to our strategic decision and then she has cost us about one.
Some of that sport of incremental girl.
I just pdps was wonderful fault, you for 43 cents per share and $1.46 I see our.
This was better than the outlook. We had said for 1.42 freed door lock to one for one point 44 cents per share at constant exchange rate.
The reported results include you does we disclosed last year, a pretax charge off for younger than than $2 million well nuclear reaching reserves for the Msrs, We announced in October. We don't think I was this season, two stoping tone or do you broke month old Ingeus instrumentation in light of I wouldn't you partnership we didn't even though [noise].
We have also advanced or if you shouldn't see measures during the last few months and you had to increase the adjusted operating income margin to 27.6%, although with says.
I was a nics keep on which we made good progress during 19 on improving I was somewhere between side booked 40.
As you saw recently you know what press release from early in January we reached a new milestone was more than 2500 cumulative placement <unk> for the automation system. This has really become a steady and consistent growth engine for kids and in fact, you could artisan I'm thrilled to why were leadership.
In sum, but processing and we continue to plan for more than 200, new placements into falls on a swing.
Although we saw a slow down in the fourth quarter <unk> do you feel latent you've got people see that says which was due mainly to what those trends in the Asia Pacific region.
Test odd to 40, your sense girl for 10% see our nights.
Did you broke them until the fourth quarter was U.S. regulatory approval just us it for the use of I guess or on the I guess, where we just don't system. We talked previously received European clearance back into program in it.
I will portfolio of products for use in mixed in there were some sequencing achieved I will go to $410 million to $15 million in 19.
Reported to once again by the sub consecutive year old Dober did you see our girls you're not by doing promising business, which is no no no. One I was kind of ebbs and digital insight.
How does a lot of key message.
We provided yesterday, our outlook for two falls on and Twinge.
And you see is clearly aligned with what we discussed with you or you know where Q.
Goals net sales are expected to grow about 3% to 4% C. O four before your as I mentioned before we have set targets that balance growth opportunities and I won't put forward. Your we've got what challenges in particular, all the ongoing weakness over what sign that business and expectations for a full.
The reduction in the revenues from companion diagnostic co development due to the change is not when next generation sequencing strategy.
At the same time, we expect you expecting wouldn't you forecast that diagnostic to drive further placement and <unk> approval on that that yes are we were thrilled to translate into the good conversion of course, you feel all TB testing in the U.S.
Finally, we also believe that that where you wouldn't have short ngs. Both toward your we did you grow double digit growth in Nigeria as we expand our were also.
I just did you P is expected to be about one point 52 door lock to one point 54 cents per share I see our as we continue to improve open reaching deficiencies and maintain our strategy for very disciplined capital allocation.
And now I would like to handle go through all.
Yeah. Thanks <unk>.
Moving on to those of you in Europe, and good morning throws off your ones yes.
I'd like to go over all key financials for the fourth quarter and for the full year 29 team.
Let's see all to the fourth caught off 2019, well falling about such important 5 million U.S. dollar just falls a 4% increase.
Change bread and butter <unk> <unk> <unk>.
That's cool on a reported basis plus 2% just supposed to do some modest adverse currency had been coming from a combination of counties.
Oh, sure <unk> and South Korea involved.
For the full you off 2019 net sales fell 1.5 billion U.S. dollar rising 4%.
Well what 2018.
<unk> business Jets calls was 2% absorbing about two percentage points of costs you have to them.
Oh dogs income statement.
Just to close modules nearly two percentage points was 71.6% don't feel it's a false caught off 29 team from 69.8% <unk> support the parts of solid performance <unk> lodging comes over business is 7% see alcohol.
For the yield just cosmological 71.
Per cent compared to 70.7% in 28, <unk>, which remains at a strong level, especially as we are supporting multiple new product launches.
Adjusted operating income in the fourth quarter or 16% to wonder about 38.6 million U.S. dollar off shoring significant improvement or the same Pete and 2018 impart due to the savings generated by the change in orientation of our Ngs try to cheat and targeted efficiency programs season.
Through the discontinuation off on Ngls instrument development programs, which frees up about 70 million U.S. dollar it's on a full year on the way it which is partially being reinvested.
The adjusted operating income margin boss, Saudi 3.5 cents for the false caught up 29 picking up from 29.6%.
Yep Yep.
For full year 2019, adjusted operating income was 5% to follow up 21.8 million U.S. dollar.
For about $2.3 million.
<unk>.
Just logic adjusted operating income margin of 27.6% for 2019.
Patrick 26.9% in 28.
Adjusting for <unk> adjusted Onyx 'cause shale the false caught off 29048 cents at constant exchange credits and the <unk>. It sets of extra days is supposed to develop off all the 45 to 46 cents. It's yeah.
For the full year adjusted ARX <unk>, a $1.46 cents at sea I'll answer that Ross counts you had that's the justice policies sense to $1.43 cents actual daisy.
As we mentioned Kaleo Nonsmoker robots uplift smartstrand charges would be tick primarily into sort of false caught off of 29.
The vast majority offices charges or couple of on your partnership let me now and our decision to discontinue development all future at U.S. based instruments.
I love charges for tick as part of a decision to ship all production organization into a regional structural and also truck spent activities at our Kaiser business shouts sell the Sun belt in Poland and the Philippines.
As it has all doses initiatives.
It takes a structure shots on $24.9 billion on operating income for the fourth quarter of 29 team.
This means we took a toll shops, you about 2 million U.S. dollar <unk> operating income.
For 29 gene.
George I was just shots well call it 68% involves noncash charges primarily due to.
The decision to discontinue ngs instrument development.
The drops off Cashel operating cash flow decline for 29 into strong see about $3.8 million compared to see about 59.5 million U.S. dollar 2018.
Long as a key factors like cash payments for the restructuring initiatives and higher tax payments pots of sales tax audits for prior years.
Code for the past.
Excluding the cash restructuring payments for the measurement knowledge and for what 2019 operating cash flow was see about 68 million U.S. dollar.
Investments and Poppy Plaza next it but were also higher on 2019 rising to one on about 17.9 billion. Your best told us from button. It up 9.8 billion you asked a lot from 2018, there's supposed mainly due to investments to build top manufacturing capacity to support new product launches.
As it was art free cash flow declined to one up 12.9 billion U.S. dollar and 29 team.
What about $49.7 billion from 28.
Moving to the balance sheet at the end of 2019 or leverage ratio stood at <unk> 0.6 times net debt to EBITDA. This will slightly higher than 11 <unk> fourth types at the end of 2018.
Continued to see Qiagen is having a very healthy balance sheet, which can absorb more leverage to support business expansion initiatives as well as she have approached us programs and increasing returns.
I would like to know reviews, phillips's odds basin ought to product categories.
Custom us into life science and molecular diagnostics.
A lot geographic regions.
<unk> product categories sales of consumable goods and related revenues was a strong 7%.
Oh, I see about $64 million into fourth quarter couples that 88% fields.
Well, it's largely in line with the trend for the full year, 2019, which fills up 6% see up to 1.5 billion U.S. dollar and a couple of exempting, 89% upscale.
Instrument sales also had dawn, 16% see out to 49 million U.S. dollar into fourth quarter of 29, King and the Cup event, the 12% Duff <unk> Phelps for the full year instruments were down 5% <unk> 29 to two one I'm not 72 million U.S. dollar loss and I've got presented to 11% of store.
Itself.
This does decline was expected due to our decision to subject to change orientation apologies, we though and you have system and also due to <unk> revenues from struck potty instruments office contracts.
It's the same time, we're seeing good trends.
Rental agreements, which instruments placed with considerable but can you talk instead of capital equipment approaches.
This should translate into salad kits and consumables cells in the future.
It's a molecular diagnostics customer Clos fields for the fourth quarter off 29.
People since the out to 198 billion U.S. dollar represented 48% of solar cells.
Yeah, we saw mid single digit CEOC gains in consumables and all that.
Related revenues, but also a double digit see object Triton instrument sales.
You mentioned a.
A key negative effect of whats the 29 to declining revenues from companion diagnostic co development project pharma companies.
Revenues totaled 54% see out to $9 million the false caught off 2019.
Excluding these specific revenue was molecular diagnostic sales went up about 10% see hot in the fourth quarter.
For the full year 2019, molecular diagnostic sales were up 4% Tee up and also represented 40 I said that fills.
The growth plus weighted down by a 27% see a decline in companion diagnostic core development revenues.
42 million U.S. dollar off.
Excluding these specific revenues molecular diagnostic sales were up about 7% see off what 2019.
It's a life science customer classes, so ongoing solid twit solid trends in the fourth caught up with Fiat's rising 4% see a two to one of $16 million, representing 52% off told says.
Yeah Life Science, that's about 5% G 29000, 789 billion U.S. dollar and also represented 52% off towards kids.
Within the life Sciences sales to follow a custom us was 5% see odd defaults caught off on mid single digit CEOC Wolf contributions pumpkins robots and related revenues and in particular benefited from the expansion of <unk> <unk> and U.S. portfolio.
It's like a day me applied testing customer class, where ops people since Oh.
I would like to know overviews of as odds that well see geographic regions.
The Americas region lets the performance in the fourth caught off 2019, rising 7% see out 280 million dressed alone.
Presenting 44% off sales. So you asked the live on Wolf in lives. This region supported by doubled you did see gains in Mexico for the yields a medical school, 5% see are reaching seven on about 22 million U.S. dollar loss.
<unk>, 47% doctoral itself.
Europe Middle East Africa region was 5% see out to one almost 46 million U.S. dollar and the fourth quarter represented 75% toward itself.
Saw improving trends in a number of western European countries, and Patrick the law flops, United Kingdom in Germany, and also solid trends and talkie. However, we saw double digit.
Declines in Italy, and Switzerland.
Drop in Italy was related to that changed.
TB distribution center gene utility in the fourth quarter 2018 to Tyler.
For the full year sales in the region were up 5% see out to Florida 7 billion Youre still lots of draw started to Percentof total itself.
The ongoing decline in China, as well as a significant slowdown in Japan, and molecular diagnostic, whereas a key reasons for the Asia Pacific, Japan region, slowing or 4% see odd tried and failed to $87 billion $87 million for the false caught off 29 team.
You may recall aside from the discontinuation of our China reduction Benshaw. We also had issues when some of our distributable false floor dawn and payments coming in from their own custom lots and hospital laboratories.
During the fourth quarter 2019, you put wanted to like plants in place to address this issue.
For the year growth in the Asia Pacific, Japan region, So to 2% see up which you can see about 14 million U.S. dollar I don't know presenting 21% of sales like for now had back to tell you.
Thank you at all thanks, a lot and I would love I would know like she will give you an overview on the fourth quarter you updates for the full Walter.
So we're thinking about what collaboration we start yesterday.
As we said before we received a view approval in November 2019 for the automated workflows over the course, you feel on TB gold close test on the digest screen views on she stemming the ways.
He's worked through also streamlined level that the Rio to me, some 40 ton TB screening and she portfolios or convert from from two broken instead to our modem bloke base quantity feeling technology. We see these are the based loud scale solution available for lease term TB testing.
I work companion diagnostic good development business Wesfarmers, he's going through a transition period due to the changing that were ngs threat there.
But I would like to insist that we continue to attract a lot the business based old or not with truck we called the in creating PCR based test and then he does industry leading platform. We can you actually putting you on that topic.
As a recent when we enter <unk> strategic agreement with Amgen do do you look tissue based companion diagnostic for their investigation or concept preesman to identify Bisha, Wisconsin that Todd the key Ross.
Gee 12 see mutation.
Agreement focusing initially on companion diagnostic for non small cell lung cancer, but we are low fulfilled strategy real pent up that for amgen's always looked into co development programs.
You know knows the partnership we have expended I would put up where we shouldn't be logical regarding the use of cash flow Gen DG toward insights solution.
The agreement now includes an extension of the current Caojing Teeny coating side license. We use that were human gene mutation database, you know three improve identification any degradation of genetic variance we inherited diseases.
This expansion views on the existing seven year relationship between the two companies to do you broke.
Introduce and she bought new diagnostic test.
Indeed, I really Oh, what 40 or expansions to you. We have launched then you can see murchie Matador partners to complement our existing universal Ngs solution, which can be used with 80 sequencing platform in the world.
These current <unk> only solution that can be used to extract.
And the reach and sequins D N the volumes and it when they fusions as well as to assess gene expression either single work flow from the Singur Semper.
In support of both Ngs MPC our reputation we have launched an agreed invest one of the didn't look design and I know he sees herb.
These combines cure rates you know what age we content based assays and then that is.
It also provides a tool to life science research shows for the complete side, but you must go targets exploration custom panic configuration and older rigs I was weighed I've decided that you see some planning oh follow up experiments.
In bioinformatics didn't think restaurant and of one you know completed I'm glad you didn't give you talking side I was expanded distinction of Soviets Eastern Europe.
See I presume she's running sites now includes yeah may still guidelines and <unk>.
Approved on code, which draws and he's a very board in Europe from what do you put up I thought it would just on quarter, just a mini cogen agencies.
Next well, yes that diagnostic has made good progress as a platform offering fast cost effective and fleet keyboards syndromic testing.
Just over your after launching the European market and just over half of your into your ways. We are already about to reach the follows on total cumulative placement that we present, an average of 200 placements per quarter.
Also showing Saudi placement raised Easter kinda acute coronary platform provides you go told me to December to prepare restrict yourself to lower throughput needs overlap or.
Got you act, you'll be very ideally complement to cat yesterday.
I'm kinda back to connect was launched in early two fold them in nitrogen and has already reached over 600 on 60 placement.
These platform is the next endeavor, we spend of cardiac James widely used cardiac cube, three month, which has over 8000 placement worldwide.
Indeed, the cone systems group of KFC, putting young kids acute connect underscore the strength of our sample prep six metallurgy vote for you.
Moving into two falls and I'm 20, we have some key new products that we expect to complement existing bought for you.
And contribute to where we're doped line Dcs and for the coming years.
No. The board opportunity you see I were entry into the Gigi toward PCR World.
We are on track for me to falls on Mtwenty launch well by well nobody is treatment, which we'd be branded as cardiac queasy.
Drink prelaunch previews, we have received positive feedback from customers and hobby, even pick a first orders.
These 40 integrated digital PCR workflows, we'd be supported by hundreds of catching assays and all designed to deliver a key advantages for one of the fastest growing get realized in their life Sciences industry.
Well unique Mendo play technology has been created to Ofer close to 15 wait for labs to have faster and easier access to a distinct notes.
We are seeing as I said before very positive you need shorter buckets response.
Interesting early access is running very high and the first older. He's already in place for a major U.S. pharma company.
The features on my work I got Queasy solution, we meet the needs of current digital PCR users and enable us to accelerate congrats on from the mills larger contract that cheap Pcr markets.
In particular that English teacher.
Got Ya that diagnostic he's really having a growing popped into syndrome 15 market.
We will continue to drive growth can be installed base, we do we need to new partners of too far into following in twin.
The G by guess.
Got it throwing 15 or already marketed in Europe has been submitted to do you have yet in December and there are 40 is expected to launch in the U.S. These first type of did your.
In Europe, Dominion's actually starting to become Tracfone come after launching the first hats off to falls Mtwenty I was with.
Each menu additions of use the odds value for more customers.
I did evolving capabilities for at least for no indications.
The cost you feel TV franchise, we are ready to support the expansion of modem TB testing into low resource Hi, Bill done there we as we do we these or by work once you feel when would you be accessed solution.
New system is designed to advance your book because she's going forward in areas with limited infrastructure using a device that we've always done needs for gorge, saying, a computer or a continuous power supply.
<unk> expense is expected to launch in the last part of to follow that I'm 20, I see I did you so who shop.
To quantify it won't jeebies momentum.
And now I, we'd like to have you don't go back to order.
Thank you Charlie I would like to know if you all outlook for 2020 and for the fourth quarter I'll see you that's north of the all the Oh 2020 cost one that's that's cool off approximately 3% to 4% CEOC will.
<unk> outlook takes into consideration of arc walking cogent Sop in set portfolio, partially offset by significant headwinds from a anticipated that but you should see declining companion diagnostic co development revenues due to the new orientation for our Ngs strategy.
The outlook also takes into consideration expectations for lower felt in China. The first half off 2020, mainly due to the slow down in autos from distribute does that forgotten in mid 2019, and send off the China Ngs trunk bench and Austin 29 team.
Seeing an increasing global demand for solutions that can be used for the Corona virus testing. We have not included in our outlook for 2020, given the uncertainties and disruption that this time overall business trends in China.
<unk> outlook does not take into consideration any future acquisitions, including the potential acquisition of remaining stake in automotive Ics for approximately 274 million U.S. dollar switch the option that expires in mid 2020.
Our outlook for JUXTAPID, we want to eat the S is $1.52 cents to $1.54 cents, <unk> shale, which which school for about 2019 at a significantly faster pace since Sept schools, we tend to invest some of the savings from stopping the ngs instrument develop.
Programs into the business, but also let something drops to improve operating profitability.
As for currencies based on the rates as of January started from 2020 and drops off net fields. We expect the currency headwind of about one percentage 0.1 of those odds at actual rates for adjusted EPS for the full year. We also expect accounts he had somewhat of a bottom concept tissue.
For the fourth quartile owe us outlook is for <unk> that sell scope of ought to just people said he or she was driven by expectations for solid cool the life Sciences, along this underlying improvements in molecular diagnostics that ought to be overshadowed by the <unk> expected in China and films are companion.
I can gnostic co development revenues.
Adjusted diluted EPS is expected to be about 28 to 29 cents per shell at constant exchange rates.
It said in terms of currency impact for the fourth quarter all based on rates as of January started from 2020, you expect tepid of about one to two percentage points on that fits for up to about one cents on adjusted EPS was that I would like to have back to treat.
Thank you were at all and think Youre for your attention now before we move into the QNX Fisher and I'd like to summarize quickly the content of our work order.
First of all I need to was really of crucially important not only for a whole only myself, but the rest of the executive committee and the until you're comparing.
And we delivered on the says outlook for the fourth quarter and full year, two fulghum and Nigeria, and we delivered on what we could lead.
True if I were last go together.
Good underlying growth across the portfolio was hindered by business trends in China as we disclosed in Q3 last your that began in mid two falls on a night vision and the reduction in revenues from Ngs based companion diagnostic co development project, but do you see spot clearly about west strategy for Ngls as we disclosed in nature.
You know that went partnership we didn't even though.
We also exceeded our target for adjusted earnings supported by Sittings Didnt reach either through our change in NGL strategy and goes very few cents you msrs and they didn't see there do you see is also something which is crucial for rolling myself.
Whatever I will still plan reserve, we always told me talk you see two did you go to <unk> improvement of profitability.
Additionally, we continue to have a clear focus on value creation and cold by our commitment to discipline kept you towards the problem.
And that's your last point, we are looking for more growth in sales and adjusted earnings into Fulghum Mtwenty, taking into account what that could realistically ambitious approach to sitting targets and especially they leave a ring quarter after quarter on that were commitments.
These I'd like to hand back to draw Downs, you'll pay for itself would your Korea and they Fisher. Thanks set up for your attention.
Ladies and gentlemen.
Well begin the question answer session anyone.
Good question.
Followed by one on their Touchtone telephone.
If you wish to withdraw your question you May press star followed by till.
To ensure we can accommodate as many people that's possible. Please limit yourselves to only one question.
One follow up your microphone will also be needed after you finish asking the questions.
The one who asked the question May Press Star one at this time.
My first question from Bill Quirk of Piper Sandler.
Great. Thanks, and good afternoon, everyone.
So.
First off 2020 revenue guidance roll into can you talk about some of the major assumptions that are dialed into this for example, how much of a drag as the previous now it's China and Ngs changes have to the underlying or how does that affect relative to the underlying girls that go forward business.
And then separately, we appreciate that you're not including any impact from Corona virus, because it's still early but if we think about this outbreak potentially expanding on consistent with some of the leach data that just came out any framework for how we can think about some scenarios here. Thank you.
I suggest that a things before the question I suggest that the Orland says your first question is on the up a assumption and then I will take the current harvests are question or not.
<unk>.
Hi, Bill I think all that said that's a set before we feel reasonably comfortable for the year 2020, it's quite up yes, that's really hasn't changed since Oh announcement. This is soft quarter was all that he believes it probably takes us a up to three caused us to walk tall underlying.
China issuing the pick out the molecular side lopsided side or to the fourth quarter was actually quite a reasonable got more or less a flatter school for tee up quite a bit call. It takes some time to block or some of this inventory situations. We see this discussed the most you know in shot on the molecular outside so I think that is clearly one large assumption.
And then it should go back to a more normalized cool off with a in the second half let's see on.
On the companion side I think we clearly expect can somewhere between 10, and 15 million <unk> million U.S. dollar happens this year compared to last year you finish yes, we set a there so on 42 million U.S. dollar.
Revenues and the whole discontinuation of RG <unk>, a French fries pulled it gets also kind of five for 7 million dollar had tremendous about you have seen the middle East like we just continue to smaller part up all business next door, which is a lot about a five minute dollar franchise because of some I'll discontinued.
Nation fastball, so there's a cut off line had been factor for us.
It's the same type of cost we have a a large launch in mid office yesteryear set before August it should PCR kind of stop is clearly something what do you expect that never day to double and also allows like Wolf drive us, particularly clung to fear on and also when you asked should do quite well just see as well.
So I believe it to the Corona virus I think it's fair to say, that's it's a it's it's a bit premature because.
I mean, unlike many companies we have kept a rather low profile in communication at the moment because.
Personally I don't want you were.
Oh go communicates when we are faced with the property Cat challenge, but you can you imagine that because of the nature of our portfolio, we are extremely aktiv or even providing differentiated insurance in China, but outside of China, I'm talking to ctcs or companies in China that Dr. currently provides.
Being a sign that we said 15 solution. We that were 40 some percent <unk> solution, both instrumentation and ER and also are going to me books.
It's fair to say all showed that ER, it's oh views that kinda then he is working on different 15 solution for their current I've I was.
On different option, either Singur, Blake's, which is for US is okay. Yes, you put me on your projects or a which is our priority at the moment syndromic or solution.
Combined with our where we speak about the reported that.
Or on that Okay, yes, that's what we've shown that I'm I'm I have been handling toast and that each quarter performance report on got you broke aren't I'm quite proud to say that calculation would have ER SGT format test ready.
In the coming weeks insight into them on <unk>.
So there are pluses and minuses minuses to take into account that Oh views that we see an increase of deliveries to our fall somewhere about where extraction and consuming vote at the same time as you know algae.
It couldn't make activity in China, I slowed down considerably even GP court no to find flights to Delever into China. I mean, these are we fight week by week to make sure that were product can get there. So so far a bit premature.
There are two balance movement, and we we don't usually updates as we go but I wouldn't like to pick a bet on do you have the woman.
Well take our next question from Tyco Peterson JP Morgan.
Hey, Thanks, I'm going to start with quite a fear on obviously you know notable slowdown here can you talk on trends both in the U.S., where youre up just high single digits has there been any impact on the quest relationship given their their deal with Oxford and then more importantly on the adverse trends in China, and Japan, and what is baked into guidance for quanta.
When should we still think about it just kind of 15%.
And then secondly for Roland I'm, just can you clarify what's embedded in guidance for China on gross I didn't hear a number for you and then any update on cost initiatives and how you see the cadence of margin expansion over the remainder of the year. Thanks.
Okay perfect. So so on on quality federal first time in growth profiles for a per region. So first of all.
Are we still see if every sodium or growth of course, you feel more in the Iwear North American markets. We are finished the year.
Close to 17% growth or in North America, driven by both girls in what we called the national account or including Quest.
And also the hospitals, so we have not seen any detrimental impact of the Oxford Immunotec Quest.
Every month and I see that quest is sticking to what they say that many months ago that the we'd want to continue to offer a those two solutions to their north American customer.
In Europe, or we are absolutely from two base effect for Q4, two falls on a 19 at Coffeyville to falls on anything to call. It took to fall Gonna nights in basic a whole only spend one of them. A you might remember that we had a distributor already told you a company called <unk> Dot and we decided to transfer that.
These nice to digest serving.
In December of two for kind of 18 first a basic picked second base effect.
We also implement either new distribution network for the Nordic countries in Q4 of 18 and that creates a a sick can be they compare to Q4 two falls on a night.
D. A really shouldn't be that yes are we in is going well.
You wrote it started in Europe budget as we have said today and that's you know when we presented at the.
Oh, yes are we encourage and agreements we always said that we would probably you know to protect costs you feel orange is a growth drivers for kinda then we would basically ER I been done no drug with Buffalo by where did you take trying to prevent used to digest or when do you see is what you have seen the beach in Europe for immediate impact on what's going to up.
I think they're coming month fees that we have agreed with I guess, we're going to move you wrote two or more extensive drops shipments strategy, which will prevent these two happened or getting too far with them and 20 I'm coming years sign up or is a weaker as we said are still be goes over that.
Distributor all during a decline due to smoking issue than we are working on that I strongly believe that there were a inventor we used to high in China, I said I commencement partners and we didn't know to put that into the market. That's the strategy for the coming month I was all said in quality film, but they're still photos are active.
Yes, we take.
Until the end of Q2, two they definitely are clean that so that's would explain.
The Pro Friday night.
For the coming years, we could only be.
The quantity film franchise, you still double digit good old ER franchise, but now we are closer as we said in Q3 and also we know when New York imaging close to 10% to 12% growth for your which mean was supposed to warn that when you are on the franchise or more than two under.
And in 16, and a $14 million, we're going to use Dobermans you tend to quit 10 to 12, she's very healthy and synchrony means also that you didn't growth is not just a a quantity Phil tell you I didn't know wasn't murchie board engines of growth that the whom you go to relate once you feel we talked about.
Yes, we obviously talked about kinda seemed when we talk more and more to both caveats that NW. She did you see toward PCR all for the second how called the question.
Yes, I can say so first of all I'm shine a enough cost just to remind you of one more time tyco, it's what I'm going to say what now it's kinda excluding the potential upside if you might have on a go when a virus, but it's also excludes a quench adult side, which might be do which was a general business trends.
At least comedies he wasn't on China, because if you set a lit bit or too early to to come your to any conclusion, but given on modest on all experienced also saw them fourth quarter I seem to go uses carries a fourth quarter, we have seen an improved when compared to the sort caught on China as you know and the so called I've got to I think at minus 26.
Offend kind of cool wet in China thinking that fourth quarter wasn't on modest it's a 9% cool wet in China, So somebody improvement and as I said before it's more or less all and the extra I'm really not much show on life science.
In terms of negative impact and we do all to expect or that we should expect yet and the pool, but modest quarter by quarter going back to what we believe there's a new normal which is probably a kind of a 10 plus percent cool wet or by end of 50, Oh, we have to see how that falls in August.
The overall China.
You see before.
Margins are probably little bit easier to answer what now are we also expect already that the first quarter, we stopped quite strong.
Comes off margin improvement.
I think we should have at least your onto two on that business margin improvement <unk> adjusted operating margin compared to the first quarter lost you know.
So its policies or 20 425 percentage points for the first quarter.
Also for the full Youre seeing we should see a nice margin improvement of at least on 75 basis points.
Clearly driven by a change in trumps all R&D expenses are we talked about this change and our strategy along to next generation.
Sequence of developments.
I'm going to reinvest some of this savings again or what about.
$30 million on the run rate a into sales and marketing activities, particularly I want all launch activities. That's you know we have.
<unk>, one coming out to this digital PCR, where we believe you have an outstanding opportunities and they just want to make a lot or clears up the that these supports that.
As well.
Okay.
Next the steep shot at Wolfe research.
Hi, good afternoon, they're in and thanks for the time I wanted to focus on on Kious stat.
I want to do you can speak to in your modeling for this year and if you're up into it beyond this year or you think about modeling the highest at throughput over time given your this very rapid growth of the installed base.
Which naturally grows the denominator and then down stream of that how you think about evolving highest add it to be a higher throughput instrument will be impacted that and what would that means the model and then just one last quick one.
For rolling in your assumptions for this year, but do you assume that in the aggregate that instrumentation revenue.
Great. Thanks, so much.
Okay, I will take the one on kind of thought or.
Hope that I understood. What you really mean by who could hear so you. These old views that we are pleased with GE you've got most of the installed base. We said close to a if I was going to seize them. It's a good growth bicuar 30 to grow by quarter, which is comparable to the one of our main competitor about your failure, but we do that with less menu.
As a reminder, or we might do we have to test approved in a in a <unk> de in Europe, and we have one thats whats your I pod.
Got to be putting it in North America.
This oh, you see in store base give us a C or your sliver rage as soon as we're going to launch more menu show or suggest in Europe meningitis sic 'em test in the U.S. Wheeze G.
We do see mine, we really believe that got yes that should doble. The performance that we achieved into falls on a 19, which was around 15 million.
No laws on the reach around stretching media D. C is completely logix chord with I think those revenues and the growth of the buckets itself.
We are already view of usually thinking or about to how your food or generation.
We have a as a matter of fact conduct <unk> or an intense market surveys are wrong depend on solution for a in the last week. So we know exactly the design of the she's done we want to bring to the musket deceased they will not she does not get probably before I would prefer to said you end up too.
Collagen and 21, because it takes some time will you see too do you grow Pete so well do the profile of that franchise I would refer to what we said in New York, which was if you remember the combined revenues of around 850 million for new movie 10, Ks, Dod and that you're always highlights.
That own Dot Gov started by two fold and a 23 should be around 200 million Ah. So it's Chris you want to what we said I think it's potentially beat the board we continue to bring new assays under such as Jos goals, such <unk> number one yeah.
Look I'm sure a positive I'd or.
By now and we are also as I said before working we're sort of them codes, yet or do you broke my guys went to extend to potential beyond the infectious disease as their last thing I just have you need to eyewear two falls on Mtwenty free a guidance in New York between your body extend the catalyst that I remind you old that the numbers that we gave two.
Date for the guidance 20 years without than you would use or acquisition is just the just we'd be shouldn't when your projects I think she's now.
Have you done so your question.
Kim jumps off instrumentation growth, what I think we will see a are quite some change over the color for you.
The factor for that is actually twofold first of all of cost a lot and all we have a significant portfolio of port Arthur I don't want I'm sorry.
You see a larger ships through we attend rentals and that's one thing and the second topic off causes you still have to digest.
Lets the discontinuation of or do you know we don't franchise here.
But the second topic, which is probably much more partners. We also expect that's it did show you see all platforms I'll watch much most fit for what capital filled.
So a lot so short or we expect probably for the overall instrumentation cool wet in life as a company growth wet, but coming from a low a number the Philadelphia.
Well take our next question from Doug Schenkel at Cowen.
Hey, guys. Thank you for taking the questions. So really just a few cleanups. So make sure we're understanding some of the embedded assumptions and guidance correctly.
First on Quanta fear on and of course. This is really important given the long term importance to your growth profile and yeah in focus given the performance in the fourth quarter. So I just want to confirm I I think you said this in answering tychos question, but I just want to confirm that you're assuming quite a few different growth.
We'll be nominal in the first quarter due to the tough comps and a continuation of what you saw in the fourth quarter and that for the year, you're assuming less than 10% or around 10% Kwan if you're on gross.
And then the second thing as it relates to quantify fear on the long term target of 10% to 12% that you talked about I just wanted to make sure that means the 400 million dollar revenue target for 2023 that you outlined at your analyst day last summer is no longer on the table.
And then on HPV the last part.
Based on your commentary last night, it looks like global HPV sales were actually over $50 million for the year, which I think what actually represent growth versus 2018 for that franchise could you just talk about why that business is holding up better than expected and what you've embedded into 2020 expectations. Thank you.
Yeah, Let me let me so every quickly.
Oh, no weekend or you always have to take you put on do you want me to ticket.
Now, let me stop estates Privy to get set off or way and I never go from there, yes, we set a edge it could be actually was about 50 million. Yeah. I was a lumpy 55 million dollar French I've spent 29 tend to be clearly.
Lets say a I've seen you had some impact but I think it's also fair to say that the expect you if something happens often in 2020. So I think our overall assumptions a a SPV is still there where we all the sat but again as you can feel that it's also business, which clearly has a still the quite some likes to accept.
Fiscal stimulus.
But as I said strategically I would was I expect you also have come for 2020 coming up.
Yeah, I ought to of course you.
Yeah for once it's also the last thing on Expedia word on that.
[music].
Let's not forget that H.C., two or what technology you see the week of nice doesn't go to stand up on the buckets. What do you of course, you know why sometime we all know decline. He got spots is that because that's what I'll say, some Q account, especially around the national accounts in the U.S. ousted using that technology and a and that was solution, but we we still bet on the decline over overrode gear up to you.
Sure.
<unk> I confirmed that we are.
I believe that to fall gonna nttwenty, we'd be around that the budget growth for a 10% or.
In that a adjustment of a.
Growth.
We are in the long tempted to focus on and 23.
Probably are just to be true up to 400 million, but I'm still optimistic that these numbers that she they bought for two reasons.
Because you guys don't that 400 million, we get in New York did not really fully factored the potential impact of I will like assays that we are still developing with our friends at best So reason and as you know we won't do have that's what I'm trying to they bought at least for the European market by two fold and I'm 20 warm.
The second thing is that these 400 million them good doesn't fully 40 or take into account the potential of the quantity people walk says 40 ton TB. It is very difficult to assess the exact put 10, shorting hi, built and low resource countries. So we prefer to take a conservative stance, but.
She is why I believe it stayed within weeks yes.
Well go next to Dan Brennan, Yes.
Hey, Thanks for thanks for taking the questions first one was on the strategic review.
You announced a process following the third quarter call. So I was hoping to get some insight.
On the review I know you recently, just consider Brocal conference have you decided I think after extensive board review to walk away from the process because discussions did not just fill your criteria. So could you just elaborate a bit.
But the criteria, where they didn't get met was a price or other factors, which you can kind of highlight from high level and also what factors could potentially lead to board to Reengage with interested to teach you parties.
In particular, we understand there was no standstill agreement put in place post conclusion of the discussions and then just one follow up on China, I know you've already addressing issues there, but the <unk> related to the distributor Destocking issue.
Highlighted there was some factors with the hospitals and lab customers that led to that doesn't exactly clear what drove that could you just elaborate a bit was it came in specific was there something industry wide regulatory and kind of whats the visibility for this issues to be resolved. Thank you.
The first part on the on the strategic discussion. So as we said many times I will go. These oh, you see fully aware of their fiduciary responsibility and they will continue to are exempt <unk> that that a fiduciary responsibility one of the key factors for these strategic discussion.
We have in November and December is clearly GBT T N D to feasibility we always say the that we didn't want to other kind of done bookies world on catch and for many months with no visibility on the deal and that seemed at the recent example, Oh you mean that backed by you or proves that we are quite right on that.
For a China, we said that Oh.
As you know I were ER distribution is mainly no 100% mean, mainly done through a or distributors, what we called commensurate buff knows that collision.
And what we explain these that in the Q2 of 19 Hospital staff T to pay those distributors, we delays and as a consequence that there's people very effect on cogen doors distributors decreased their old dose to catch him.
At the same time as we said, that's where we realized that we had some stock inventory. She was that due to distribute those and we set to clean died and this is what we said he's going to take before between that probably between two to three quarters to sort that.
I think as I said or so even though you know what Q3 cool the Chinese market remains largely on track to either it's a very good market I Vg only in vitro diagnostic it's at least a 4 billion musket no you see the growing at double digit do you only opinions that before we were seeing the buckets were seeing probably grows.
20% to Europe, My assumption is closer to 10% to 15% now so we see the buckets, where can we continue to invest.
[noise] Scott.
[music].
Yeah. Thanks for taking my questions since that's crushing really a follow up.
Okay calls the takeout.
I think that normally when a border and I'll come to me or walk away from several take I'd go approaches in preference for stands lunch strategy. Its usual cool the bold and a complete to communicate this the underlying proposition that the company to the financial market.
Now take into consideration that the company has deviated from the the loss made some climbing gym by two fiscal annoyed, saying then the such in your guidance. This year should we now expect communication from the company about realistic medium term perspectives to create value.
That's question one place second question specific question on NIM OPX, there's nothing much like this.
So then the presentation today I Wonder if you can give us an update as to how that's performing in Europe, how the legal challenges that becton Dickinson a guy.
That's all it so happens.
Thank you.
So I propose thank you for the question I propose I would stick and what do you extend or don't she wants to step in for the first part of the question or on on the strategic discussion Pneumovax, we still see are very favorable acknowledgment and welcome.
By not only European customers by the way, but we also put the system in many is yeah.
Countries with as we disclosed as well.
In Q free.
We were expecting.
To have access to the HIV test much sooner, we were expecting that test in 2019, and it didn't come and you saw big Bucks you could not really runs because especially when you ends up to 10 does.
For example, like in Europe, you need to answer Weezer foolish.
What we cord blood borne virus your spend there which is HBV it's TV.
HIV, we had the edge BV, we have the H.C.D., we didn't have the HIV we couldn't.
Run for those standards.
But again the customers I really thinking that keeps a differentiated platform and he said that that value platform.
So as you know we have an option to.
Finalize the acquisition of a g., we mini 80% of shares.
Over Pneumovax.
Do you see sito solution that we really promote on demosky She's Tito solution that we really like at the same time, we want to clarify the delivery boy Oh, My strong, especially in menu and also do clearing of de situation, we becton Dickinson before <unk> picking the final decision.
Well.
Yes 60.
Scott to very thoughtful question I guess.
Yes, I think our communication on December 24th books very straight forward in the same time I think they gave us various pitfall I'd like you just seconds before that all responsibility that all bought two you know what's the bought defeated show responsibilities I think I would like to add ons that that security. All bought is also fell away I bought a disclosure of us.
The abilities as well and I think it's exactly what they're doing right now I see became fall, but with the guidance for the full year.
I think that is something what put off the plants as it is as of today.
And that is something wherever you want to deliver on ticket from you guys are you hot both of US, saying today, we clearly want to brings a company back to a trajectory wherever you're going to meet and hopefully beat our targets or time and I think that as the main focus loss.
Well go next to Brian Weinstein at William Blair.
Hey, guys. Thanks for taking the questions couple from here just first can you just update us on the CEO search timing and and any thoughts there and then second on the portfolio in general is there any additional pruning that you guys are considering ahead of that and you mentioned that there was an opportunity to potentially take.
Every job so is there a willingness to do any deals right now or is that completely off the table so tightly.
So so on the CEO search.
I mean as I said many times as you know the decision is in the hands of the Bulls eye.
I reaffirm that you'd so here, we had see a process for a company that size I know that brand.
You have a competition between different solution.
Outside or inside of Cogen.
What is important to me at the moment is that a there is a team.
There is an executive team and there is a c. you in place.
And that being said I expect that process to be will go up by Q2 of this year as we always say.
As we got to pruning the.
Both for you.
We always said all showed that we ought to meet the kept competitors.
It doesn't meet got company I really believed that there were priorities would be to focus and focus and focus again, only where we can take meaningful leadership position, we I'm not here on the market to mimic what the bigger companies are doing show induce a mindset.
Everything we just not considered as completely contributing to that typically people always picking leadership position, we'd probably be divested a a kinda then you have seen recently that we announced the or as sad about were mixed style activities.
That's are typically exempt there's no as far as didn't making for the future. I mean anytime you are going to make sense for carriage and which is.
One reinforcing I wouldn't put 40, you either in life science molecules are or what we called digital audience sites now.
And when it really is going to be I create teeth very quickly for carriage. Then we are always open to talk but it has to be completely coherent with what we have it has to reinforce what we have and it has to allow us to.
Pick those.
Leadership position on the market.
Well go next to down areas at Stifel.
Hi, Thanks for the questions Terry as Illumina outlined the way in which the sequencing I say collaboration will work now that they're also aligned with.
Oh gosh in that area, what specific focus or or division of labor. There and then just secondly role and if you've mentioned that have already apologies, but did you state the revenue expectations for digital PCR This year, if they're arnie.
Okay or don't tend to take the answer on digital PCR rates are very simple one oral.
Yeah sure no we haven't stated it.
Yeah, there's little bit to all it but I do believe set that depending but other launched it.
But it should be a again high.
Seven digit low double digit <unk> billion dollar amount.
Yeah. Thank you need to work on that the solution will be fully launches a sticker front for the year. So.
And to your first question to even though.
So you are you remember that we always said that we were bringing two companies to expertise to gives or one of these instrumentation. She's you leave me. That's taken is another one is a sequence you give me suite and and I insist on this one expertise in companion diagnostic and that BD team.
To bring those companion diagnostic to a P M prove or all to regulatory approval. This is your sense of did you do is even though we always said as well that I wouldnt priority on that deal was first and foremost companion diagnostic.
And this is where we are currently forecasted.
We also disclosed that I were really shouldn't where did you mean I was pardon application you remember we said first focus on Koji inside oncology companion diagnostic, but we had the right for infectious disease and always or application that quickly.
What I know from D. Roshi, let me now or agreement is that that agreements. These restrict that you won't grow GE, but do you see is my reading, so I'm not making comments here, but the reading is that its respective to encouraging so I seem to the.
Yeah, Dan you didn't mean agreement as larger but they're getting.
First Fukushima companion diagnostic disease was we said today and also in Q3.
It goes we believed that the right strategic decision for catch him to take because its freeing up resources for all those little more meaningful investments we have accepted to see a decrease of eyewear and she is based companion diagnostic revenue for probably too.
We used to do you have had a hard and we we progress easily.
Feel that decrease we that were companion diagnostic or solution. We should give me that and we always said that we expect the first companion diagnostic. Indeed. It was you give me not to combine the Q4 of two falls on Mtwenty Yep, Okay with that I'd like to end the call we run a little bit long, but we wanted to get your question.
Thank you very much for your interesting cage and and please do not hesitate to contact the IR team you have any questions or comments. Thank you.
Ladies and gentlemen, this concludes the conference call. Thank you for joining and have a pleasant day Goodbye.
[music].